| Literature DB >> 25598505 |
Christopher J Cheng1, Gregory T Tietjen2, Jennifer K Saucier-Sawyer3, W Mark Saltzman3.
Abstract
The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25598505 PMCID: PMC4451203 DOI: 10.1038/nrd4503
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694